Current Partners

Grann Pharmaceuticals develops nucleic acid based treatments for patients afflicted by cancer, neurodegenerative and immunological diseases.

Alcheme Bio provides analysis services and media supplements to enhance the flavor profiles of cultivated foods.

Keystone Therapeutics is developing transformational drugs to redefine patient outcomes, beginning with hard-to-treat solid cancers. Our proprietary platform technology enables us to design effective therapeutics that accumulate at a disease site. As a result, we can treat with a small dose and achieve superb efficacy and safety, all while leaving healthy tissues unharmed. Lanuaria’s drugs have the potential to revolutionize the treatment landscape of cancers with high unmet medical need in the growing multi-billion solid tumor market. Our team is highly experienced and purpose-built with a common mission to save and improve the lives of patients.

We are proud to be a premier institution for botanical science and conservation, both within the Garden and beyond our 37 acres. Our major projects fall within three pillars: native plants, medicinal plants, and food and agricultural plants. Working in our nurseries and out in the field, ongoing activities of focus include conservation horticulture; seed banking; rare plant and habitat surveying, monitoring, and collecting; characterizing, evaluating, and distributing plants; environmental restoration; conservation planning; and science outreach and education.

Alpha Young is a biotech company focused on developing novel biologics to treat metabolic disorders and aging. Our main program focuses on restoring phosphate metabolism during kidney failure.

Developing redosable mRNA therapeutics to treat diseases at its molecular origin.

Developing multi-target Rx oncology drugs leveraging the power of natural compounds (phytopharmaceuticals).

#